Urgent Call for Enhanced Precision Oncology Acc...

By João L. Carapinha

March 5, 2026

EFPIA White Paper: Unlocking Precision Oncology Access in Europe The EFPIA Oncology Platform's white paper, "Advancing Precision Oncology Treatment and Testing Across E...
Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU
Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Manage...
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
EMA’s mCombriax Vaccine Recommendation
HERNEXEOS Lung Cancer Treatment: First FDA Approval for HER2-Mutant NSCLC
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 T...
Infarmed Regulatory Activity: January 2026 Highlights and Impacts on Market A...
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
Economic Impact of Industry Clinical Trials in Europe
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
Enhancing Systematic Reviews: AI Literature Review Integration for Efficiency...
Administrative Court Error Complicates Infarmed Vaccine Data Transparency